Literature DB >> 17560163

Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.

Wen-Hui Cao1, Xiaogan Wang, Lucien Frappart, Dominique Rigal, Zhao-Qi Wang, Yan Shen, Wei-Min Tong.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that catalyzes the poly(ADP-ribosyl)ation of target proteins in response to DNA damage and has been proposed to play a role in DNA repair, recombination, transcription, cell death, cell proliferation, as well as in stabilization of the genome. We have recently shown that PARP-1 deficiency causes mammary tumorigenesis in mice. In the present study, we investigated whether genetic variants and single nucleotide polymorphisms (SNPs) of PARP-1 contribute to human breast cancer. To this end, we screened all PARP-1 exons, 7.1kb of intron-exon junction and 1.0-kb promoter sequences in 83 French patients with breast cancer and 100 controls by direct sequencing of genomic DNA. Twenty rare genetic variants of PARP-1, including c.1148C>A (Ser383Tyr), c.1354C>A (Arg452Arg), c.2819A>G (Lys940Arg) were detected in nine (10.8%) breast cancers of these patients. Among 31 polymorphic sites examined, five haplotype-tagging SNPs (htSNPs) of PARP-1 were identified. Interestingly, the genotype distribution of htSNP c.852T>C (Ala284Ala) was likely associated with loss of estrogen- and progesterone-receptor expression. The present study implies that genetic variants of PARP-1 may contribute to breast cancerogenesis and that PARP-1 htSNP c.852T>C (Ala284Ala) may influence hormonal therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560163     DOI: 10.1016/j.mrgentox.2007.04.011

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  17 in total

1.  Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.

Authors:  Hongping Yu; Hongxia Ma; Ming Yin; Qingyi Wei
Journal:  Genet Epidemiol       Date:  2011-11-29       Impact factor: 2.135

2.  Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Authors:  Tasha R Smith; Wen Liu-Mares; Beth O Van Emburgh; Edward A Levine; Glenn O Allen; Jeff W Hill; Isildinha M Reis; Laura A Kresty; Mark D Pegram; Mark S Miller; Jennifer J Hu
Journal:  Carcinogenesis       Date:  2011-06-23       Impact factor: 4.944

3.  Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population.

Authors:  Ping Yu; Yun-Peng Liu; Jing-Dong Zhang; Xiu-Juan Qu; Bo Jin; Ye Zhang
Journal:  Tumour Biol       Date:  2014-09-02

4.  DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.

Authors:  Preetha Rajaraman; Amy Hutchinson; Sara Wichner; Peter M Black; Howard A Fine; Jay S Loeffler; Robert G Selker; William R Shapiro; Nathaniel Rothman; Martha S Linet; Peter D Inskip
Journal:  Neuro Oncol       Date:  2009-12-10       Impact factor: 12.300

5.  PARP1 polymorphisms increase the risk of gastric cancer in a Chinese population.

Authors:  Wenting He; Tao Liu; Yong Shan; Kexiang Zhu; Yumin Li
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

6.  Racial and tissue-specific cancer risk associated with PARP1 (ADPRT) Val762Ala polymorphism: a meta-analysis.

Authors:  Noel Pabalan; Ofelia Francisco-Pabalan; Hamdi Jarjanazi; Hong Li; Lillian Sung; Hilmi Ozcelik
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

Review 7.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

8.  Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.

Authors:  Francine Durocher; Yvan Labrie; Geneviève Ouellette; Jacques Simard
Journal:  J Hum Genet       Date:  2007-10-18       Impact factor: 3.172

9.  The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients.

Authors:  Ilhan Onaran; Gülçin Tezcan; Levent Ozgönenel; Esra Cetin; Alper Tunga Ozdemir; Gönül Kanigür-Sultuybek
Journal:  Rheumatol Int       Date:  2008-11-22       Impact factor: 2.631

10.  PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

Authors:  Kristine M Frizzell; W Lee Kraus
Journal:  Breast Cancer Res       Date:  2009-11-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.